分析米力农联合左西孟旦与联合新活素治疗顽固性心力衰竭的疗效对比

Analysis on the Comparison of the Efficacy of Milrinone Combined with Levosimendan and Combined with Xinhuosu in the Treatment of Refractory Heart Failure

目的对米力农联合左西孟旦与联合新活素治疗顽固性心力衰竭的疗效进行分析对比。方法方便选取158例于2019年4月—2020年5月收入院的顽固性心衰患者,根据随机分配法分为两组,即为M组和N组(各79例患者),M组给予米力农联合新活素治疗,N组给予米力农与左西孟旦联合治疗。比较两组患者的电解质与肾功能水平、心功能水平、治疗效率、不良反应。结果用药前两组电解质与肾功能水平差异无统计学意义(P>0.05),用药后N组全天尿量(2.65±0.52)L与Na^(+)水平(142.59±5.63)mmol/L高于M组(2.05±0.41)L、(137.45±4.80)mmol/L,差异有统计学意义(t=8.053、6.175,P=0.001);用药前两组心功能指标差异无统计学意义(P>0.05),用药后N组LVEF(41.13±6.36)%及SV水平(59.91±5.67)mL高于M组(38.28±7.01)%、(50.11±7.63)mL,差异有统计学意义(t=2.676、9.163,P<0.05);N组治疗总有效率96.20%高于M组81.01%,差异有统计学意义(χ^(2)=9.029,P=0.003);N组不良反应情况3.80%明显少于对照组21.52%,差异有统计学意义(χ^(2)=11.220,P=0.001)。结论治疗顽固性心衰患者应用米力农与左西孟旦或新活素治疗均可被临床认可,米力农与左西孟旦治疗所引发的并发症较少,就治疗效果而言,米力农与左西孟旦联合应用的效果稍高于米力农与新活素联合。

Objective To analyze and compare the efficacy of milrinone combined with levosimendan and combined with neoactive in the treatment of refractory heart failure.Methods 158 patients with intractable heart failure admitted to the hospital from April 2019 to May 2020 were conveniently selected and divided into two groups according to the random allocation method,namely,group M and group N(79 patients in each),and patients in group M Milrinone combined with Xinhuosu was given,and patients in group N were given milrinone and levosimendan combined treatment.The electrolyte and renal function levels,heart function levels,treatment efficiency,and adverse reactions of the two groups of patients were compared.Results There was no statistically significant difference in electrolyte and renal function levels between the two groups before medication(P>0.05).After medication,the urine volume of the N group(2.65±0.52)L and Na^(+) levels(142.59±5.63)mmol/L were higher than that of the M group(2.05±0.41)L,(137.45±4.80)mmol/LL,the difference was statistically significant(t=8.053,6.175,P=0.001);there was no statistically significant difference in cardiac function indexes between the two groups before medication(P>0.05),LVEF(41.13±6.36)% and SV level(59.91±5.67)mL in group N were higher than(38.28±7.01)% and(50.11±7.63)mL in group M after treatment,the difference was statistically significant(t=2.676,9.163,P<0.05);the total effective rate of treatment in group N 96.20% was higher than that in group M 81.01%,and the difference was statistically significant(χ^(2)=9.029,P=0.003);adverse reactions in group N 3.80% was significantly less than the control group 21.52%,and the difference was statistically significant(χ^(2)=11.220,P=0.001).Conclusion The application of milrinone and levosimendan or neoactive in the treatment of patients with refractory heart failure can be clinically recognized.The treatment of milrinone and levosimendan has fewer complications.In terms of the therapeutic effect,the effect of the combined application of milrinone and levosimendan is slightly higher than that of the combination of milrinone and Xinhuosu.